Ozempic and Wegovy are the same molecule—semaglutide—manufactured by the same company, Novo Nordisk. They are not the same product. Different FDA-approved indications, different maximum doses, different formulary placements, and different payer coverage patterns mean that which one a patient receives often depends more on their insurance plan than on clinical preference.
This comparison is for access teams, prior authorization coordinators, and prescribers who need to understand the practical differences between the two products when navigating coverage.
Short answer
| Ozempic (injection) | Wegovy (injection and tablet) | |
|---|---|---|
| Active ingredient | Semaglutide | Semaglutide |
| FDA indications | Type 2 diabetes, CV risk reduction (T2D + CVD), kidney disease risk reduction (T2D + CKD) | Chronic weight management, CV risk reduction (CVD + overweight/obesity), noncirrhotic MASH (accelerated approval) |
| Max dose (injection) | 2 mg weekly | 2.4 mg weekly (standard), 7.2 mg weekly (Wegovy HD) |
| Formulations | Subcutaneous injection, oral tablet (rebranded from Rybelsus Jan 2026) | Subcutaneous injection, oral tablet (25 mg, approved Dec 2025) |
| Commercial coverage | >80% of plans cover for T2D | Varies; many plans restrict or exclude for weight management |
| Medicare Part D | Covered for diabetes/CV/kidney indications | Covered for CV risk reduction; not covered for weight loss alone |
| List price (approx.) | ~$935–$1,000/month | ~$1,350/month (injection) |
| PA required | Yes (100% of plans) | Yes (where covered) |
FDA-approved indications
The critical difference: Ozempic is approved for diabetes-related indications. Wegovy is approved for weight management, cardiovascular risk reduction in non-diabetic patients with CVD, and MASH.
Ozempic indications
- Glycemic control in adults with type 2 diabetes (SUSTAIN program, approved 2017)
- MACE reduction in adults with T2D and established CVD (SUSTAIN-6, approved 2017)
- Kidney disease progression and CV death risk reduction in adults with T2D and CKD (FLOW trial, approved January 2025)
Wegovy indications
- Chronic weight management in adults with BMI ≥30, or ≥27 with at least one weight-related comorbidity (STEP program, approved June 2021)
- CV risk reduction in adults with established CVD and overweight/obesity without diabetes (SELECT trial, approved March 2024)
- Noncirrhotic MASH with F2–F3 fibrosis in adults (accelerated approval)
- Wegovy HD 7.2 mg for weight management (approved March 2026)
- Wegovy oral tablet 25 mg for weight management (approved December 2025)
A patient with type 2 diabetes should generally be prescribed Ozempic, not Wegovy, for the diabetes indication. A patient with obesity but no diabetes should be prescribed Wegovy, not Ozempic. A patient with both T2D and obesity may have either product covered depending on the primary documented diagnosis and the plan's formulary rules.
Coverage comparison by payer
Commercial insurance
| Factor | Ozempic | Wegovy |
|---|---|---|
| Formulary inclusion | >80% of commercial plans | Many employer plans; self-funded plans vary by employer |
| Typical tier | Specialty (Tier 3–4) | Specialty (Tier 3–4) or excluded |
| PA criteria | T2D diagnosis, step therapy, labs | BMI threshold, lifestyle documentation, step therapy, diagnosis-specific criteria |
| Off-label coverage | Rarely covered for weight loss | N/A (weight management is on-label) |
| Typical copay with savings card | $25/month | $25/month |
The diabetes vs. weight management coverage gap creates a practical two-tier system. A patient with type 2 diabetes can often access Ozempic with manageable copays. A patient with a BMI of 35 and sleep apnea who needs Wegovy for weight management may face formulary exclusion or high out-of-pocket costs—even though the active ingredient is identical.
Some providers work around this by prescribing Ozempic off-label for patients with obesity who also have insulin resistance, prediabetes, or metabolic syndrome. This is a clinical decision that depends on the prescriber's judgment and the plan's tolerance for off-label PA approval. Many plans will still deny it.
Medicare Part D
| Factor | Ozempic | Wegovy |
|---|---|---|
| Covered for T2D | Yes, on most formularies | Not applicable |
| Covered for CV indication | Yes (T2D + CVD) | Yes (CVD + overweight/obesity, no diabetes required) |
| Covered for weight loss alone | No | No |
| Covered for MASH | Not an approved indication | Plan-dependent |
| 2026 out-of-pocket cap | $2,100/year (IRA) | $2,100/year (IRA) |
| Medicare GLP-1 Bridge eligible | No | Yes |
The Medicare GLP-1 Bridge (July 2026)
On May 7, 2026, CMS announced the Medicare GLP-1 Bridge, a temporary nationwide program running July 1, 2026 through December 31, 2027. Wegovy is included (along with Zepbound KwikPen and Foundayo); Ozempic is not eligible because it is not approved for weight management. Eligible Part D beneficiaries with obesity (BMI ≥30) or overweight (BMI ≥27) with qualifying conditions (heart failure, CKD, prediabetes, prior MI, stroke, or symptomatic PAD) pay a $50 monthly copay. Participating manufacturers provide drugs at a net price of $245/month.
Under the Bridge, Wegovy becomes accessible to qualifying Medicare beneficiaries for weight management for the first time. Ozempic remains available through standard Part D coverage for its diabetes and cardiovascular/kidney indications.
Medicare covers Wegovy only when prescribed for the cardiovascular risk reduction indication. The SELECT trial showed a 20% reduction in MACE (HR 0.80, 95% CI 0.72–0.90) in adults with established CVD and overweight/obesity without diabetes. This evidence basis is what opened the Medicare coverage pathway.
Medicaid
Medicaid coverage for both products varies by state. Most states cover Ozempic for type 2 diabetes with PA. Wegovy coverage for weight management is more restricted and in many states unavailable. Some states (New York, California, Massachusetts) cover Wegovy for obesity with strict PA criteria. Other states (Texas, Florida, Georgia) exclude all weight loss medications from Medicaid.
Dosing and formulations
| Ozempic injection | Ozempic tablet | Wegovy injection | Wegovy HD injection | Wegovy tablet | |
|---|---|---|---|---|---|
| Doses | 0.25, 0.5, 1, 2 mg weekly | 1.5, 4, 9 mg daily | 0.25, 0.5, 1, 1.7, 2.4 mg weekly | 7.2 mg weekly | 25 mg daily |
| Max dose | 2 mg weekly | 9 mg daily | 2.4 mg weekly (or 1.7 mg if intolerant) | 7.2 mg weekly | 25 mg daily |
The higher Wegovy doses (2.4 mg and 7.2 mg) are not available under the Ozempic label. If a patient needs semaglutide 2.4 mg for weight management, the prescription must be for Wegovy, not Ozempic. This is not interchangeable.
Cost comparison
| Ozempic | Wegovy | |
|---|---|---|
| Approximate list price | ~$1,027/month | ~$1,350/month |
| Savings card (commercial) | As little as $25/month | As little as $25/month |
| Self-pay (NovoCare Pharmacy) | $349–$499/month | $349–$399/month |
| Patient Assistance Program | Free (uninsured, ≤200% FPL) | Free (uninsured, ≤200% FPL) |
The list price difference reflects the higher dose (Wegovy uses more drug substance per pen at 2.4 mg vs Ozempic's 1–2 mg). Novo Nordisk announced list price reductions for both products in February 2026.
The commercial coverage landscape is shifting
A GoodRx analysis reported by NPR in April 2026 found that approximately 12 million commercially insured people lost coverage for Wegovy and 12 million lost coverage for Zepbound between 2025 and 2026. Many employers and insurers tightened GLP-1 formulary rules, moved GLP-1s to higher tiers, or added weight-loss exclusions.
This contraction disproportionately affects Wegovy, which depends on weight management coverage. Ozempic's diabetes indications have been more insulated from these changes. However, some plans are also scrutinizing off-label Ozempic prescribing more aggressively, requiring documentation that the prescription is for an FDA-approved diabetes or cardiovascular indication.
What to monitor
- IRA price negotiations: Semaglutide (Ozempic and Wegovy) was selected for Medicare price negotiation in January 2025. Negotiated prices would take effect in 2027 and could reduce Part D costs for both products.
- Medicare GLP-1 Bridge rollout: Monitor CMS guidance on the July 2026 launch, eligible populations, and participating Part D plans.
- Commercial coverage contraction: GoodRx data show 12 million people lost Wegovy coverage between 2025 and 2026. Monitor employer plan changes during open enrollment.
- Oral formulations: Wegovy tablets (25 mg) and Ozempic tablets (rebranded from Rybelsus) expand formulation options. Coverage for the oral formulations is still being established across plans.
- MASH confirmatory data: Wegovy's MASH indication is under accelerated approval. Monitor for confirmatory trial results and any FDA label actions.
Sources
- FDA, Ozempic prescribing information: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209637s035,209637s037lbl.pdf
- FDA, Wegovy prescribing information: https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s029lbl.pdf
- FDA, Wegovy CV risk reduction approval: https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-reduce-risk-serious-heart-problems-specifically-adults-obesity-or
- FDA, Wegovy HD 7.2 mg approval: https://www.fda.gov/news-events/press-announcements/fda-approves-fourth-product-under-national-priority-voucher-program-higher-dose-semaglutide
- Drugs.com, Ozempic FDA approval history: https://www.drugs.com/history/ozempic.html
- Drugs.com, Wegovy FDA approval history: https://www.drugs.com/history/wegovy.html
- PMC, Coverage and PA trends for GLP-1 therapies: https://pmc.ncbi.nlm.nih.gov/articles/PMC12397888/
- KFF, Wegovy Medicare coverage: https://www.kff.org/medicare/a-new-use-for-wegovy-opens-the-door-to-medicare-coverage-for-millions-of-people-with-obesity/
- UnitedHealthcare, Wegovy PA criteria: https://www.uhcprovider.com/content/dam/provider/docs/public/prior-auth/drugs-pharmacy/commercial/r-z/PA-Non-Formulary-Wegovy.pdf
- Novo Nordisk, Wegovy savings offer: https://www.novocare.com/patient/medicines/wegovy/savings-offer.html
- Novo Nordisk, Ozempic savings: https://www.ozempic.com/savings-and-resources/save-on-ozempic.html
- Novo Nordisk / PR Newswire, Medicare GLP-1 Bridge announcement (May 7, 2026): https://www.prnewswire.com/news-releases/wegovy-access-expanded-for-medicare-beneficiaries-living-with-obesity-through-the-medicare-glp-1-bridge-starting-july-1-2026-302764949.html
- NPR, Patients struggle to pay for obesity drugs as insurance coverage slips (April 2026): https://www.npr.org/2026/04/22/nx-s1-5794613/health-insurance-wegovy-zepbound
